|
We asked 40 pharma leaders, should FDA be forced to make changes in how it regulates the drug industry?
| Strongly agree |
43% |
| Agree somewhat |
14% |
| Disagree somewhat |
29% |
| Disagree strongly |
14% |
 |
|
|
|
|
|
|
|
28 August, 2012
|
| In this Issue |
Why the Pharma Sales Force is Due for a Revival
Eric Janvier and Wendy van der Lubbe ask how traditional sales forces can be best utilized in a new model of customer-centric engagement. Read more... |
Study 'Confirms Economic Viability' of Orphan Drugs
Orphan drugs achieved blockbuster status in 2011, generating over $50 billion, and have the potential to generate as much lifetime revenue as drugs used for more common health conditions, according to a report from Thomson Reuters' IP & Science division. More... |
The US Vice Presidential Candidate: Healthcare Reform Controversy
Paul Ryan's naming as presidential candidate Mitt Romney's running mate has fuelled controversy in the US over his views on Medicare. More... |
The UK's Plans to 'Export' the NHS: More Olympic Fever?
It looks like the UK coalition government has been as affected by the misty-eyed portrayal of the NHS in the London Olympics opening ceremony as the most romantic patriot in the audience. It's now planning to export the NHS 'brand' around the world "to raise funds for patients at home and raise the international profile of the health service." More...
|
ICH Announcement Buried Among Summer Distractions
Summer is traditionally the period of vacation and distraction - and when people are distracted and vacationing, they don't always give their customary attention to what is going on back at the office. Which is why they may have missed a very interesting development in international drug regulation, tucked away inconspicuously in a press release issued last month. More...
|
|
|
|
